Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The primary goals in the management of hypertension, angina pectoris, and postinfarction cases are to prevent further damage to the cardiovascular system and to reduce the risk of subsequent myocardial infarction. Of all the drugs currently available, the beta-blockers seem the most likely to achieve this aim. The search for new beta-blockers centers around the need for agents that offer the advantages of beta 1-adrenoceptor antagonism without the unwanted beta 2 effects, which may be dangerous in asthmatic patients and may make bronchitis, diabetes, and arteriopathy worse or more difficult to control. One solution is to use a selective beta 1-adrenoceptor antagonist. Another is to develop a molecule that acts as an antagonist at beta 1-adrenoceptors and as an agonist at beta 2-adrenoceptors. celiprolol is such a "third-generation" beta-blocker in that it combines both attributes, and thereby offers a clinically relevant advance. It does not seem to disrupt glucose homeostasis or exacerbate peripheral vascular disease, the lipid profile appears to be positively altered, and the risk of bronchospasm is reduced. Celiprolol is therefore both clinically and biochemically well tolerated.
 ...
PMID:Pharmacology of third-generation beta-blockers: greater benefits, fewer risks. 248 89

The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis. Even the lowest dose of bisoprolol (5 mg) caused a marked, long-lasting reduction in blood pressure and heart rate. After doses exceeding 20 mg, the incidence of an exaggerated pharmacodynamic effect on heart rate (beta 1-blockade) increased with dose. At doses above 30 mg, bisoprolol showed incipient impairment of bronchomotor function (beta 2-blockade) in individual patients. It is concluded that bisoprolol exhibits high beta 1-selectivity, i.e. a wide beta 1/beta 2 split, since blockade of bronchial beta 2-receptors only occurred at doses well above the therapeutically relevant dose range. The results may not be applicable to chronic treatment.
 ...
PMID:Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. 614 38

Tachycardia in the asthmatics and bronchitis patients is very frequently observed. Atenolol-beta 1 selective beta-blockers, have little lipophilicity and intrinsic sympathetic activity and relatively long acting. It is known that atenolol more then other beta-adrenergics decreases frequency of cardiac rhythm even in a doses which have not antiarrhythmic nor hypotensive action. Atenolol effect on airways resistance was studied in patients with chronic bronchitis and bronchial asthma determining the heart rate, pulse and atrial blood pressure and the vital capacity (VC), forced expiratory volume (FEV1%VC), value of maximal expiratory flow at 50% of VC(MEF50) thoracic gas volume (TGV) and bronchial resistance (Rt). A statistically significant difference in the measurements of heart rate and pulse but no rise of the airways resistance after 25-50 mg atenolol per day was observed.
 ...
PMID:[Atenolol in the treatment of patients with airway obstruction]. 959 40